Nonetheless, it is interesting to observe the further results assessing the efficacy and safety profile of other prostate cancer specific antigens-based ADCs, such as sacituzumab govitecan along with CD46-based and B7-H3-based ADCs. This evidence concerns the gene CD276 and prostate carcinoma.